• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Transgender health and the impact of aging and menopause
Climacteric. 2023 Apr 3:1-7. doi: 10.1080/13697137.2023.2176217. Online ahead of print.ABSTRACTGender affirming hormone therapy (GAHT) is used by many transgender people to reduce gender incongruence and improve psychological functioning. As GAHT shares many similarities with menopausal hormone therapy, clinicians supporting people through menopause are ideally placed to manage GAHT. This narrative review provides an overview of transgender health and discusses long-term effects of GAHT to consider when managing transgender individuals across the lifespan. Menopause is less relevant for transgender individuals who take GAH...
Source: Climacteric - April 3, 2023 Category: Geriatrics Authors: A S Cheung B J Nolan S Zwickl Source Type: research

The impact of micronized progesterone on cardiovascular events - a systematic review
In conclusion, while available data suggest that MP as a component in combined MHT may have a neutral effect on the vascular system, more RCTs investigating the impact of MP alone or in combined MHT on vascular primary endpoints are needed.PMID:35112635 | DOI:10.1080/13697137.2021.2022644
Source: Climacteric - February 3, 2022 Category: Geriatrics Authors: L M Kaemmle A Stadler H Janka M von Wolff P Stute Source Type: research

Current Perspective on Menopause Hormone Therapy and Cardiovascular Risk
AbstractPurpose of reviewIn past decades, there has a been a paradigm shift concerning menopause, hormone therapy (HT), and cardiovascular disease (CVD). While initial observational studies suggested hormone replacement to provide a cardioprotective benefit for all menopausal women, subsequent large randomized trials have not confirmed these benefits and furthermore brought to light the risks of HT with regard to CVD, venous thrombosis, and stroke. The goal of this review is to summarize current recommendations regarding HT as it pertains to cardiovascular risk.Recent FindingsMenopause HT remains the most effective treatme...
Source: Current Treatment Options in Cardiovascular Medicine - May 5, 2021 Category: Cardiology Source Type: research

Assessment of Cardiovascular Risk in Transgender Patients Presenting for Gender-Affirming Care
The transgender population is rapidly growing in the United States and abroad. Transgender men and women are marginalized as a result of their transgender status with resultant health repercussions. This and other factors such as increased substance use, mental health disorders, violence, and chronic stress may place transgender individuals at higher risk for cardiovascular disease. Additionally, many transgender patients pursue gender affirming hormone therapy which has been linked to increased rates of some cardiovascular events such as metabolic syndrome, venous thromboembolism, and stroke.
Source: The American Journal of Medicine - April 22, 2021 Category: General Medicine Authors: Kara J. Denby, Leslie Cho, Karlo Toljan, Meghana Patil, Cecile A. Ferrando Source Type: research

Fezolinetant in the treatment of vasomotor symptoms associated with menopause
Expert Opin Investig Drugs. 2021 Mar 16. doi: 10.1080/13543784.2021.1893305. Online ahead of print.ABSTRACTINTRODUCTION: Although international clinical practice guidelines recognize a continued role for menopausal hormone therapy (HT), particularly for symptomatic women <60 years of age or within 10 years of menopause, safety and tolerability concerns have discouraged HT use due to potential links with a perceived increased risk of hormone-dependent cancers, and an established risk of stroke and venous thromboembolism. There is therefore a need for safe, effective non-hormonal therapy for relief of vasomotor symptoms (...
Source: Expert Opinion on Investigational Drugs - March 16, 2021 Category: Drugs & Pharmacology Authors: Herman Depypere Christopher Lademacher Emad Siddiqui Graeme L Fraser Source Type: research

Cardiovascular Risk/Benefit Profile of MHT.
Conclusion: CV risk calculation should be considered by clinicians in order to exclude patients with high CV risk, in whom MHT is contraindicated. Assessing risks and benefits in a patient-centered approach according to individual's features, health status, and personal preferences is important in order to realize a safe and effective treatment. PMID: 31500138 [PubMed - in process]
Source: Medicina (Kaunas) - September 5, 2019 Category: Universities & Medical Training Authors: Villa P, Amar ID, Shachor M, Cipolla C, Ingravalle F, Scambia G Tags: Medicina (Kaunas) Source Type: research

Pages: 1  2  3  4